|RFx ID :||24327669|
|Tender Name :||Future Procurement Opportunity – Supply of aripiprazole, COX-2 inhibitors and prednisolone|
|Reference # :|
|Open Date :||Q2 2021|
|Indicative RFx Release Date :||Q2 2021 [?]|
|Tender Type :||Future Procurement Opportunity (FPO)|
|Project Status :||Awaiting approval [?]|
|Indicative Total Value :||$5M - $10M [?]|
|Tender Coverage :||Sole Agency [?]|
|Required Pre-qualifications :||None|
PHARMAC Procurement Team
PHARMAC intends to issue a competitive procurement process for the supply of aripiprazole tablets, prednisolone tablets and COX-2 inhibitors, specifically celecoxib and etoricoxib.
Responses for each chemical will be evaluated individually, i.e. there is no requirement for any one respondent to supply all chemicals.
Aripiprazole tablets and celecoxib are currently funded, and not subject to Special Authority funding criteria.
Prednisolone tablets and etoricoxib are not currently funded.
The approximate gross annual expenditure (ex GST) for each chemical in the 2020 Financial Year was:
Aripiprazole - $903,000
Celecoxib - $1,558,000
Etoricoxib - not currently funded, some percentage of the celecoxib expenditure may move to this chemical over time if a response is accepted.
Prednisolone - not currently funded, some percentage of the prednisone expenditure (not in scope of this procurement) may move to this chemical over time if a response is accepted.
Prednisone expenditure was $356,000